Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tivozanib + paclitaxel
- Development stage
- Unknown
- Lead developer
- AVEO Oncology
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Tivozanib + paclitaxel is a combination of two anticancer agents used in clinical research for the treatment of solid tumors, including metastatic breast cancer. Tivozanib is an oral, potent, and selective small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3. By inhibiting these receptors at subnanomolar concentrations, tivozanib blocks angiogenesis and lymphangiogenesis critical for tumor growth[6][8]. Paclitaxel is a taxane chemotherapeutic agent that binds to the β subunit of tubulin in microtubules, hyper-stabilizing their structure and preventing normal cell division[5]. The combination has been studied in phase I trials showing tolerability and preliminary antitumor activity in metastatic breast cancer patients who had not previously received VEGFR inhibitors[3][8].
- Other names
- tivozanib hydrochloride monohydrate
02
Targets
TUBB (Tubulin (alpha and beta subunits))VEGFR2 (Vascular endothelial growth factor receptor 2)ABCB1 (P-glycoprotein)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)ABCG2 (Breast cancer resistance protein)
Beyond the preview
Go deeper on tivozanib + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tivozanib + paclitaxel.